The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan

Cancer

Volumn 117, Issue 6, 2011, Pages 1321-1391

  Zage, Peter E ^a,b   Graham, Timothy C ^a,b   Zeng, Lizhi ^a   Fang, Wendy ^a   Pien, Christine ^c   Thress, Ken ^c   Omer, Charles ^c   Brown, Jeffrey L ^c   Zweidler Mckay, Patrick A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

AZ623; brain derived neurotrophic factor (BDNF); neuroblastoma; topotecan; trk; TrkB

Indexed keywords

AZ 623; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 79952375922     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25674     Document Type: Article

References (32)

1. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol. 1998; 16: 953-965. (Pubitemid 28108728)
2. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27: 1007-1013.
3. Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/9341/9342 Trial for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008; 51: 747-753.
4. Maris JM, Hogarty MD, Bagatell R, Cohn SL., Neuroblastoma. Lancet. 2007; 369: 2106-2120. (Pubitemid 46935947)
5. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D., Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004; 26: 227-232. (Pubitemid 38500970)
6. Barbacid M., Neurotrophic factors and their receptors. Curr Opin Cell Biol. 1995; 7: 148-155.
7. Huang EJ, Reichardt LF., Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001; 24: 677-736. (Pubitemid 32695243)
8. Nakagawara A., Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001; 169: 107-114. (Pubitemid 32595557)
9. Rubin JB, Segal RA., Growth, survival and migration: the Trk to cancer. Cancer Treat Res. 2003; 115: 1-18.
10. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003; 300: 949. (Pubitemid 36548874)
11. Schramm A, Schulte JH, Astrahantseff K, et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett. 2005; 228: 143-153. (Pubitemid 41188436)
12. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002; 62: 6462-6466. (Pubitemid 35364107)
13. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ., Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res. 2002; 62: 6756-6763. (Pubitemid 35364148)
14. Evans AE, Kisselbach KD, Liu X, et al. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res. 1999; 5: 3594-3602.
15. Iyer R, Evans AE, Qi X, et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res. 2010; 16: 1478-1485.
16. Marshall JL, Kindler H, Deeken J, et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005; 23: 31-37. (Pubitemid 39505949)
17. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004; 103: 3669-3676. (Pubitemid 38596280)
18. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor Lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006; 108: 3262-3270.
19. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010; 115: 1131-1136.
20. Thress K, MacIntyre T, Wang H, et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009; 8: 1818-1827.
21. Biedler JL, Helson L, Spengler BA., Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973; 33: 2643-2652.
22. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA., Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981; 41 (11 pt 1):: 4678-4686. (Pubitemid 12201390)
23. Reynolds CP, Tomayko MM, Donner L, et al. Biological classification of cell lines derived from human extra-cranial neural tumors. Adv Neuroblastoma Res. 1988; 2: 291-306.
24. Foley J, Cohn SL, Salwen HR, et al. Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell lines. Cancer Res. 1991; 51 (23 pt 1): 6338-6345.
25. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995; 36: 393-403.
26. Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK., Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol. 2000; 35: 468-474.
27. Donfrancesco A, Jenkner A, Castellano A, et al. Ifosfamide/carboplatin/ etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl. 2004; 93: 6-11. (Pubitemid 38570249)
28. Carol H, Houghton PJ, Morton CL, et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010; 54: 707-715.
29. Pratt CB, Stewart C, Santant VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994; 12: 539-543. (Pubitemid 24079896)
30. Miknyoczki SJ, Chang H, Klein-Szanto AJ, Dionne CA, Ruggeri BA., The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res. 1999; 5: 2205-2212. (Pubitemid 29399279)
31. Weeraratna AT, Dalrymple SL, Lamb JC, et al. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res. 2001; 7: 2237-2245. (Pubitemid 32751620)
32. Strock CJ, Park JI, Rosen M, et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 2003; 63: 5559-5563. (Pubitemid 37139878)